XML 83 R64.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award      
Granted, Weighted Average Exercise Price   $ 8.34 $ 45.56
Outstanding, Intrinsic Value   $ 102  
Stock options      
Share-based Compensation Arrangement by Share-based Payment Award      
Accelerated vesting, number of shares 90,328    
Unrecognized compensation cost related to nonvested stock-based compensation   $ 3,900  
Weighted average remaining period over which unrecognized compensation expense will be recognized   2 years 8 months 12 days  
Common Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award      
Options, Outstanding, Beginning Balance   305,838  
Granted   68,796  
Assumed in connection with Aceragen Acquisition   111,038  
Forfeited   (15,963)  
Expired   (63,535)  
Options, Outstanding, Ending Balance   406,174 305,838
Exercisable, Ending Balance   239,866  
Weighted Average Exercise Price, Beginning Balance   $ 137.08  
Granted, Weighted Average Exercise Price   8.34  
Assumed in connection with Aceragen Acquisition, Weighted Average Exercise Price   6.22  
Forfeited, Weighted Average Exercise Price   3.27  
Expired, Weighted Average Exercise Price   148.30  
Weighted Average Exercise Price, Ending Balance   83.00 $ 137.08
Exercisable, Weighted Average Exercise Price   $ 132.26  
Outstanding, Weighted Average Remaining Contractual Term   6 years 1 month 6 days 5 years 10 months 24 days
Exercisable, Weighted Average Remaining Contractual Term   4 years 1 month 6 days  
Exercisable, Intrinsic Value   $ 54  
Preferred Stock Options      
Share-based Compensation Arrangement by Share-based Payment Award      
Assumed in connection with Aceragen Acquisition   19,826  
Forfeited   (2,304)  
Options, Outstanding, Ending Balance   17,522  
Exercisable, Ending Balance   5,229  
Assumed in connection with Aceragen Acquisition, Weighted Average Exercise Price   $ 365.96  
Forfeited, Weighted Average Exercise Price   130.00  
Weighted Average Exercise Price, Ending Balance   397.02  
Exercisable, Weighted Average Exercise Price   $ 317.43  
Outstanding, Weighted Average Remaining Contractual Term   9 years 1 month 6 days  
Exercisable, Weighted Average Remaining Contractual Term   8 years 10 months 24 days  
Outstanding, Intrinsic Value   $ 1,073  
Exercisable, Intrinsic Value   $ 568